Waverly Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.71M | Buy |
33,822
+7,354
| +28% | +$1.03M | 0.04% | 419 |
|
|
2025
Q4 | $3.25M | Buy |
26,468
+3,567
| +16% | +$433K | 0.03% | 474 |
|
|
2025
Q3 | $2.54M | Sell |
22,901
-13,483
| -37% | -$1.53M | 0.03% | 466 |
|
|
2025
Q2 | $4.03M | Buy |
36,384
+3,707
| +11% | +$395K | 0.04% | 343 |
|
|
2025
Q1 | $3.66M | Buy |
32,677
+3,496
| +12% | +$361K | 0.04% | 348 |
|
|
2024
Q4 | $2.7M | Buy |
29,181
+2,320
| +9% | +$209K | 0.04% | 328 |
|
|
2024
Q3 | $2.25M | Sell |
26,861
-395
| -1% | -$30.1K | 0.04% | 315 |
|
|
2024
Q2 | $1.87M | Buy |
27,256
+801
| +3% | +$53.5K | 0.04% | 324 |
|
|
2024
Q1 | $1.94M | Buy |
26,455
+1,910
| +8% | +$147K | 0.05% | 261 |
|
|
2023
Q4 | $1.99M | Sell |
24,545
-23,818
| -49% | -$1.85M | 0.07% | 148 |
|
|
2023
Q3 | $3.62M | Sell |
48,363
-206
| -0.4% | -$15.8K | 0.16% | 97 |
|
|
2023
Q2 | $3.74M | Sell |
48,569
-826
| -2% | -$65.9K | 0.16% | 89 |
|
|
2023
Q1 | $4.1M | Buy |
+49,395
| New | +$4.09M | 0.21% | 71 |
|
|
2018
Q2 | – | Sell |
-2,893
| Closed | -$218K | – | 189 |
|
|
2018
Q1 | $218K | Sell |
2,893
-2,190
| -43% | -$174K | 0.04% | 162 |
|
|
2017
Q4 | $364K | Buy |
5,083
+739
| +17% | +$56.1K | 0.05% | 174 |
|
|
2017
Q3 | $352K | Sell |
4,344
-790
| -15% | -$60.4K | 0.08% | 168 |
|
|
2017
Q2 | $363K | Sell |
5,134
-2,304
| -31% | -$153K | 0.09% | 162 |
|
|
2017
Q1 | $505K | Buy |
7,438
+2,803
| +60% | +$197K | 0.13% | 130 |
|
|
2016
Q4 | $332K | Buy |
4,635
+573
| +14% | +$42.6K | 0.12% | 74 |
|
|
2016
Q3 | $321K | Buy |
+4,062
| New | +$330K | 0.13% | 66 |
|
|
2016
Q2 | – | Sell |
-2,578
| Closed | -$237K | – | 92 |
|
|
2016
Q1 | $237K | Sell |
2,578
-621
| -19% | -$56K | 0.15% | 71 |
|
|
2015
Q4 | $324K | Buy |
3,199
+2,443
| +323% | +$254K | 0.14% | 84 |
|
|
2015
Q3 | $74K | Sell |
756
-7
| -0.9% | -$777 | 0.05% | 97 |
|
|
2015
Q2 | $89K | Buy |
763
+13
| +2% | +$1.42K | 0.05% | 76 |
|
|
2015
Q1 | $74K | Buy |
750
+100
| +15% | +$10.2K | 0.04% | 92 |
|
|
2014
Q4 | $61K | Buy |
650
+531
| +446% | +$54.9K | 0.03% | 103 |
|
|
2014
Q3 | $13K | Hold |
119
| – | – | 0.01% | 415 |
|
|
2014
Q2 | $10K | Sell |
119
-998
| -89% | -$77.7K | ﹤0.01% | 438 |
|
|
2014
Q1 | $79K | Sell |
1,117
-36
| -3% | -$2.82K | 0.04% | 173 |
|
|
2013
Q4 | $87K | Buy |
1,153
+155
| +16% | +$10.8K | 0.03% | 256 |
|
|
2013
Q3 | $63K | Buy |
+998
| New | +$59.6K | 0.03% | 213 |
|
Other funds holding GILD
VCM
VPM
Waverly Advisors's GILD Position: Q1 2026 in Review
Waverly Advisors increased its Gilead Sciences (GILD) stake by 28% in Q1 2026, buying an estimated $1.03M and bringing the position to 33,822 shares worth $4.71M. The position accounts for 0.04% of the portfolio, ranked #419.
Waverly Advisors first reported a position in GILD in Q3 2013 and has held it in 31 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Waverly Advisors held 33,822 shares of Gilead Sciences worth $4.71M as of Q1 2026.
- Waverly Advisors bought 7,354 Gilead Sciences shares in Q1 2026, an estimated $1.03M.
- Gilead Sciences made up 0.04% of Waverly Advisors's portfolio in Q1 2026, its #419 holding.
- Waverly Advisors first reported a position in Gilead Sciences in Q3 2013 and has held it in 31 quarters since.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Waverly Advisors's 13F filing for Q1 2026, filed 15 May 2026.